In May, the House Energy and Commerce Committee passed H.R. 623, the Gabriella Miller Kids First Research Act 2.0. This legislation modifies funding for this pediatric disease research program within the National Institutes of Health to direct certain penalties assessed by the Securities and Exchange Commission against pharmaceutical companies.
Washington E-Newsletter